Telix Pharmaceuticals Limited is a clinical-stage biotechnology company dedicated to the development and commercialisation of advanced theranostic (therapeutic + diagnostic) oncology products. Our products seek to address major clinical unmet needs in the management of prostate, renal (kidney) and glioblastoma (brain) cancer.

We offer better-informed treatment decisions and truly personalised therapy through radiopharmaceuticals, which intrinsically enable superior diagnosis (imaging) and therapy of cancer.

Our product development strategy is to closely integrate and add value to standard care, reflective of the modern team-based approach to managing cancer in a clinical setting. Our mission is to help patients with cancer live longer with better quality lives.

Latest News


Telix Pharmaceuticals and Cyclotek Conclude Radiopharmaceutical Manufacturing Agreement for Australia and New Zealand

Melbourne, Australia, July 31, 2017 – Telix Pharmaceuticals Limited (“Telix”) is pleased to announce the...Read More
August 7, 2017

Telix Pharmaceuticals and Abzena Sign Licence Agreement for Abzena’s Prostate-Specific Membrane Antigen Antibodies

Melbourne, Australia and Cambridge, UK, July. 18, 2017 – Telix Pharmaceuticals Limited (“Telix”) is pleased...Read More
July 19, 2017


We're very pleased to be working with the excellent team at Cyclotek for our Australia/NZ manufacturing...


Load More...